GAL-02-221

Overview

GAL-02-221 is a BRD4 PROTAC degrader with blood-brain barrier permeability, with a DC 50 of 0.009 μM (Jurkat BRD4-HiBiT). GAL-02-221 induces proteasome-catalyzed BRD4 degradation, binds to VHL to trigger BRD4 ubiquitination, and recruits the VHL E3 ligase complex to participate in protein degradation. GAL-02-221 degrades BRD4 in breast cancer cells as well as mouse liver and brain tissues. GAL-02-221 is applicable to research related to breast cancer . (Pink: BRD4 ligand ( HY-78695 ); Blue: VHL ligand ( HY-112078 ); Black: linker ( HY-33366 )).

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Breast Cancer | Products > Signaling Pathways > PROTAC | Products > Signaling Pathways > Epigenetics | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > PROTACs | Products > Signaling Pathways > Epigenetic Reader Domain

Product Information

• Catalog No.: HY-133737
• CAS No.: 2409538-70-9
• Molecular Formula: C50H62ClN9O8S2
• Molecular Weight: 1016.67
• Purity: 99.87%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 7.25 mg/mL (7.13 mM); Clear solution
• Availability: In-stock

Source

Original product source